Patients with Type II diabetes are insulin resistant, have relatively low insulin production, or both. Without proper insulin therapy, these patients will eventually develop cardiovascular disease, chronic kidney disease, or a host of other complications. Especially for those patients where medical treatment is not readily available, it is imperative that day-to-day maintenance of this disease be as streamlined as possible. A pharmaceutical that combines GLP-1 with low doses of insulin could be a viable solution for making insulin therapy easier to maintain.
This pharmaceutical, though potentially more efficacious and safer than currently available insulin treatments, still requires regular injections. For patients in third world countries or even in developed countries without universal health care access, needle use presents a critical issue. Unless clean needles are available, patients are extremely susceptible to infection and the spread of disease. It is thus essential that future treatments be offered in non-injectable forms.